Table I.
Specificity for oxycodone, oxymorphone and noroxycodone in human plasma, urine and liver microsomes
| Matrix/analyte | Source number |
|||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| (mean peak area ratio as % of LLOQ) | ||||||
| Human plasma: LLOQ = 0.2 ng/mL | ||||||
| Oxycodone | 4.51 | 1.93 | 1.28 | 1.04 | 1.51 | 1.24 |
| Oxymorphone | 8.18 | 3.54 | 4.93 | 2.68 | 4.36 | 1.98 |
| Noroxycodone | 13.0 | 16.6 | 8.63 | 9.01 | 11.5 | 9.42 |
| Human urine: LLOQ = 10 ng/mL | ||||||
| Oxycodone | 1.02 | 0.86 | 0.37 | 0.54 | 0.25 | 0.42 |
| Oxymorphone | 3.76 | 5.52 | 2.94 | 2.47 | 1.73 | 1.90 |
| Noroxycodone | 1.90 | 1.72 | 1.75 | 1.45 | 0.93 | 0.98 |
| Hydrolyzed human urine: LLOQ = 10 ng/mL | ||||||
| Oxycodone | 7.21 | 5.92 | 3.61 | 3.32 | 1.73 | 3.69 |
| Oxymorphone | 12.0 | 10.5 | 5.59 | 5.78 | 2.00 | 2.79 |
| Noroxycodone | 6.80 | 3.94 | 3.45 | 2.08 | 1.99 | 2.12 |
| Human liver microsomes: LLOQ = 0.2 ng/mL | ||||||
| Oxycodone | 5.53 | 3.33 | 3.43 | 3.43 | 3.94 | 3.18 |
| Oxymorphone | 8.17 | 5.30 | 6.21 | 8.02 | 7.75 | 7.75 |
| Noroxycodone | 17.3 | 14.1 | 11.8 | 10.9 | 15.1 | 14.1 |
Values are from the mean of three replicates of the matrix source, which were fortified with internal standard and had peak areas determined for any signal within the retention time of respective d0-analyte peak width. Values were compared with the mean peak area ratio of 6 samples, one from each source, fortified with analyte at the LLOQ and internal standard. Source number is just a designation that varies from one matrix to another.